Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU MDR Relegates Future Government Concerns To Second Place in Germany

Executive Summary

It is election month in Germany, and the medtech industry has been busy drawing up what it wants from the inevitable post-poll coalition agreement. But all-eclipsing still are the problems that the EU MDR is causing.

You may also be interested in...



Fifth Designation Of An MDR Notified Body In Italy As EU Total Reaches 23

Italy now has five notified bodies designated under the MDR, its number close to matching the German total.

Royal Philips’ IGT Goes For The Structural Heart

Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains. 

Royal Philips’ IGT Goes For The Structural Heart

Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains.

Topics

UsernamePublicRestriction

Register

MT144430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel